Photon activation therapy.
It is suggested here that significant advantages should accrue from the use of 40 keV photons from implanted sources of 145Sm. These energies should stimulate Auger electron cascades from IdUrd, as well as produce non-repairable damage from radiosensitization. The use of low dose rates (approximately 10 rd/hr) should allow repair in normal tissues exposed to the activating photons. Utilization of this technique with brain tumors should minimize problems associated with radiosensitization of normal tissues, as CNS tissues do not synthesize DNA. The deposition of high LET radiations selectively in tumor cells provides unique advantages not available to either conventional therapy or other forms of particle therapy (fast neutrons, protons, pions, heavy ions).
D000818:Animals; D003131:Combined Modality Therapy; D006224:Cricetinae; D004583:Electrons; D006801:Humans; D007065:Idoxuridine / Q000528:radiation effects / Q000627:therapeutic use*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011827:Radiation; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011868:Radioisotopes; D012493:Samarium
D011838:Radiation-Sensitizing Agents; D011868:Radioisotopes; D012493:Samarium; D007065:Idoxuridine